New drug may boost stem cell transplants for tough leukemia
NCT ID NCT07157514
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tests a new approach for adults with relapsed or refractory acute myeloid leukemia (AML) who have active disease. It uses a radioactive drug (131I-apamistamab) combined with low-dose radiation and chemotherapy before a stem cell transplant. The goal is to see if this helps people live longer compared to standard transplant preparation. About 306 people will take part in this two-phase study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.